Dr. Jun Bao has over 20 years of combined business and science experiences. He is currently President and CEO of Impact Therapeutics. He was previously Senior Vice President and Chief Business Officer at Shenogen Pharma Group. He also serves as a member of board of directors as well as acting Chief Financial Officer. Before he joined Shenogen, Dr. Bao was Director, Worldwide Business Development, Head of China at GlaxoSmithKline (GSK). Prior to GSK, he worked at Onyx Pharmaceuticals, ICOS Corporation and Cell Therapeutics as a business development executive with progressive responsibilities. Dr. Bao also worked as a finance manager in Procter & Gamble based in Cincinnati. He received a BS in Microbiology from Shandong University and a PhD in Neuroscience from University of Kansas. Dr. Bao completed his postdoctoral fellowship in Johns Hopkins University. In addition, he received an MBA in Finance from University of Chicago. He has authored/co-authored more than 30 research publications and co-founded two start-up biotech companies. Dr. Bao serves as a board member of BayHelix (2012/13, 2018/2019).